DGIdb - VERAPAMIL Drug Record

VERAPAMIL chembl:CHEMBL6966 ApprovedAntineoplastic

Alternate Names:

VERAPAMIL
VERELAN
CP-165331
NSC-272306NA
CP-16533-1
TARKA
ISOPTIN
D-365
COVERA-HS
IPROVERATRIL
CALAN
VERAPAMILO
SECURON®
CP-165331 / CP-16533-1
ANSYR®
VERAPAMILUM
VÉRAPAMIL
pubchem.compound:2520
rxcui:11170
drugbank:00661
chemidplus:52-53-9
chembl:CHEMBL6966

Drug Info:

Drug Class	anti-arrhythmia agents
Year of Approval	1981
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antihypertensive agent

(3 More Sources)

Publications:

Tfelt-Hansen et al., 2009, Verapamil for cluster headache. Clinical pharmacology and possible mode of action., Headache
Morel et al., 1998, The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits., Br. J. Pharmacol.
Dilmac et al., 2004, Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2., Mol. Pharmacol.
Patel et al., 2005, Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca2+ responses and chemotaxis in cultured human vascular smooth muscle cells., Br. J. Pharmacol.
Beitelshees AL et al., 2009, CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response., Circ Cardiovasc Genet
Bacon et al., 1989, Potent and specific inhibition of IL-8-, IL-1 alpha- and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists., Biochem. Biophys. Res. Commun.
Xu et al., 2008, Effect of amiodarone on Kv1.4 channel C-type inactivation: comparison of its effects with those induced by propafenone and verapamil., Pharmazie
van Noord C et al., 2009, Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation., Pharmacogenet Genomics
Dahllöf et al., Characterization of multidrug resistance in SEWA mouse tumor cells: increased glutathione transferase activity and reversal of resistance with verapamil., Anticancer Res.
Aguirre Ghiso et al., 1998, Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine kinase pathway in mammary tumor cells., Int. J. Cancer
Freeze et al., 2006, State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel., Mol. Pharmacol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Bergson P et al., 2011, Verapamil block of T-type calcium channels., Mol Pharmacol
Shchepotin et al., Apoptosis induced by hyperthermia and verapamil in vitro in a human colon cancer cell line., Int J Hyperthermia
Gong Y et al., 2015, PTPRD gene associated with blood pressure response to atenolol and resistant hypertension., J Hypertens
Jacob et al., 1996, Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle., Metab. Clin. Exp.
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos
Collett et al., 1999, Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2., J. Pharmacol. Exp. Ther.
Mickisch et al., 1991, Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance., Proc. Natl. Acad. Sci. U.S.A.
Colabufo NA et al., 2008, Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents., J Med Chem
Nesi G et al., 2014, SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity., Eur J Med Chem
Perestelo NR et al., 2011, Overcoming human P-glycoprotein-dependent multidrug resistance with novel dihydro-β-agarofuran sesquiterpenes., Eur J Med Chem
Chae SW et al., 2015, Xanthone analogues as potent modulators of intestinal P-glycoprotein., Eur J Med Chem
Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod
Tang X et al., 2012, Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells., Bioorg Med Chem Lett
Gu X et al., 2012, Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors., Eur J Med Chem
Gu X et al., 2012, Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors., Bioorg Med Chem
Liu XL et al., 2008, Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein., Bioorg Med Chem
Nievergelt A et al., 2010, Identification of serotonin 5-HT1A receptor partial agonists in ginger., Bioorg Med Chem
Lou K et al., 2014, Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies., J Med Chem
Liu J et al., 2013, 20(S)-Protopanaxadiol (PPD) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs., Bioorg Med Chem
Silva GL et al., 2001, Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei., J Nat Prod
Walz et al., 1989, Similar effects of cyclosporine and verapamil on lymphokine, interleukin 2 receptor, and proto-oncogene expression., Transplantation
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Liu et al., 2003, Calmodulin is involved in heat shock signal transduction in wheat., Plant Physiol.
Chang SW et al., 2018, Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes., Pharmacogenomics J
Vandell AG et al., 2012, G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension., Hypertension
Nielsen T et al., 2008, The KCNMB1 Glu65Lys polymorphism associates with reduced systolic and diastolic blood pressure in the Inter99 study of 5729 Danes., J Hypertens
Zhao Q et al., 2008, Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population., Pharmacogenet Genomics
Beitelshees AL et al., 2007, KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)., Pharmacogenet Genomics
Wong IL et al., 2009, Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives., J Med Chem
Perrotton T et al., 2007, (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1., J Biol Chem
Price ET et al., 2011, Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study., Pharmacogenet Genomics
Block et al., 1993, Transcriptional activation of low density lipoprotein receptor gene by angiotensin-converting enzyme inhibitors and Ca(2+)-channel blockers involves protein kinase C isoforms., Proc. Natl. Acad. Sci. U.S.A.
Takemura et al., 1992, Effect of verapamil on the class I major histocompatibility complex antigen expression in K562 chronic myelogenous leukemia cells treated with recombinant human interferon-gamma., Cancer Lett.
Tsukamoto et al., 1987, Effect of calcium channel blockers and trifluoperazine on rat liver regeneration., Eur. J. Pharmacol.

VERAPAMIL KCNMB1

Interaction Score: 7.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18854753 18496125 17700361

Sources:
PharmGKB
VERAPAMIL KCNIP1

Interaction Score: 7.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18854753 18496125 17700361

Sources:
PharmGKB
VERAPAMIL PLEKHH2

Interaction Score: 1.82

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27670767

Sources:
PharmGKB
VERAPAMIL GRK4

Interaction Score: 1.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22949529

Sources:
PharmGKB
VERAPAMIL PTPRD

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26425837

Sources:
PharmGKB
VERAPAMIL NOS1AP

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19247217

Sources:
PharmGKB
VERAPAMIL KCNA4

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18604993

Sources:
NCI
VERAPAMIL CACNA1G

Interaction Score: 0.64

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16699084 19125880 11752352 21149638

Sources:
TEND TTD
VERAPAMIL CACNB1

Interaction Score: 0.61

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND
VERAPAMIL CACNB3

Interaction Score: 0.61

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND
VERAPAMIL CACNB4

Interaction Score: 0.61

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND
VERAPAMIL CACNB2

Interaction Score: 0.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Verapamil,Calan, Covera-HS

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND
VERAPAMIL CACNA1C

Interaction Score: 0.47

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880 9846638 15286207 15880143 20031608

Sources:
TdgClinicalTrial TEND PharmGKB
VERAPAMIL CACNA1I

Interaction Score: 0.34

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
17016423 17139284

Sources:
TEND
VERAPAMIL CACNA1F

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND
VERAPAMIL CACNA1D

Interaction Score: 0.23

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Verapamil,Calan, Covera-HS

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND
VERAPAMIL NR1H3

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21562465

Sources:
PharmGKB
VERAPAMIL CACNA1S

Interaction Score: 0.18

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND
VERAPAMIL LDLR

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7683421

Sources:
NCI
VERAPAMIL CACNG1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TEND
VERAPAMIL PLAU

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9579573

Sources:
NCI
VERAPAMIL ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9862768 1671173 18257545 24607999 21856049 25686592 21348461 22209486 22405646 22429509 17964170 20363635 24992153 23683834 11754602

Sources:
DTC NCI
VERAPAMIL IL2RA

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2645720

Sources:
NCI
VERAPAMIL HSPA4

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12857801

Sources:
NCI
VERAPAMIL ABCC1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19725578 17646169

Sources:
DTC
VERAPAMIL TYMS

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3436366

Sources:
NCI
VERAPAMIL IL1B

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2686646

Sources:
NCI
VERAPAMIL MYC

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1511424

Sources:
NCI
VERAPAMIL SLC2A4

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8622594

Sources:
NCI
VERAPAMIL BAX

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9354939

Sources:
NCI
VERAPAMIL GSTP1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3566185

Sources:
NCI
VERAPAMIL CXCL8

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2686646

Sources:
NCI
VERAPAMIL TGFB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
NCI
VERAPAMIL CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
9187528 21393461

Sources:
DTC PharmGKB

TdgClinicalTrial: VERAPAMIL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antihypertensive agent

Drug Class Small Molecule

FDA Approval approved

Publications:
TEND: VERAPAMIL
- Version: 01-August-2011
Alternate Names:

Drug Info:

Year of Approval 1981

Drug Class anti-arrhythmia agents

Publications:

DTC: VERAPAMIL

Version: 02-September-2020

Alternate Names:

CHEMBL6966 ChEMBL Drug ID

Drug Info:

Publications:

Nesi G et al., 2014, SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity., Eur J Med Chem

Gu X et al., 2012, Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors., Eur J Med Chem

Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod

NCI: VERAPAMIL

Version: 14-September-2017

Alternate Names:

C928 NCI drug code

Drug Info:

Publications:

Bacon et al., 1989, Potent and specific inhibition of IL-8-, IL-1 alpha- and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists., Biochem. Biophys. Res. Commun.

Liu et al., 2003, Calmodulin is involved in heat shock signal transduction in wheat., Plant Physiol.

Collett et al., 1999, Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2., J. Pharmacol. Exp. Ther.

PharmGKB: verapamil

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Chang SW et al., 2018, Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes., Pharmacogenomics J

Zhao Q et al., 2008, Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population., Pharmacogenet Genomics

Beitelshees AL et al., 2007, KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)., Pharmacogenet Genomics

TTD: Verapamil
- Version: 2020.06.01
Alternate Names:

D0R0FE TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL6966
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	Verapamil,Calan, Covera-HS
Novel drug target	Established target

blocker (inhibitory)
inhibitor (inhibitory)

blocker (inhibitory)
inhibitor (inhibitory)

blocker (inhibitory)
inhibitor (inhibitory)

VERAPAMIL Drug Record

VERAPAMIL chembl:CHEMBL6966 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18854753 18496125 17700361

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18854753 18496125 17700361

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27670767

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22949529

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26425837

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19247217

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18604993

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 16699084 19125880 11752352 21149638

Sources: TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Verapamil,Calan, Covera-HS Novel drug target Established target

PMIDs: 19125880

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Verapamil,Calan, Covera-HS Novel drug target Established target

PMIDs: 19125880

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Verapamil,Calan, Covera-HS Novel drug target Established target

PMIDs: 19125880

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name Verapamil,Calan, Covera-HS

PMIDs: 19125880

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name Verapamil,Calan, Covera-HS Novel drug target Established target

PMIDs: 19125880 9846638 15286207 15880143 20031608

Sources: TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 17016423 17139284

Sources: TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Verapamil,Calan, Covera-HS Novel drug target Established target

PMIDs: 19125880

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name Verapamil,Calan, Covera-HS

PMIDs: 19125880

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21562465

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name Verapamil,Calan, Covera-HS Novel drug target Established target

PMIDs: 19125880

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7683421

Interaction Types & Directionality:

n/a

PMIDs:
18854753 18496125 17700361

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18854753 18496125 17700361

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27670767

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22949529

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26425837

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19247217

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18604993

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16699084 19125880 11752352 21149638

Sources:
TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Verapamil,Calan, Covera-HS

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880 9846638 15286207 15880143 20031608

Sources:
TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
17016423 17139284

Sources:
TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Verapamil,Calan, Covera-HS

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
21562465

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
7683421

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TEND

Interaction Types & Directionality:

n/a

PMIDs:
9579573

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9862768 1671173 18257545 24607999 21856049 25686592 21348461 22209486 22405646 22429509 17964170 20363635 24992153 23683834 11754602

Sources:
DTC NCI

Interaction Types & Directionality:

n/a

PMIDs:
2645720

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12857801

Sources:
NCI